Literature DB >> 11114710

Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence.

M Pantic1, A Novak, D Marisavljevic, V Djordjevic, I Elezovic, A Vidovic, M Colovic.   

Abstract

Patients with acute promyelocytic leukemia (APL) show other chromosome aberrations in addition to t(15;17) but their influence on the clinical outcome is still unclear. We have cytogeneticaly analyzed 43 APL patients with t(15;17)(q22;q21), treated with all-trans-retinoic acid (ATRA) according to the recommendations of the European APL 91 Group. Additional chromosome aberrations were observed in 14/43 patients (33%) studied at initial diagnosis. These patients were designed as 'complex' karyotype group and were compared to patients with t(15;17) asa sole cytogenetic abnormality ('simple' karyotype group). The 'complex' group had significantly lower platelet count and fibrinogen level and fewer cases without significant DIC at diagnosis than the 'simple' group. Comparison of 'simple' and 'complex' groups showed significant difference in complete remission rate (76% vs 35.7%, P = 0.0148) and early death rate (24% vs 64.3%, P = 0.0141). Survival analysis showed that the presence of additional chromosome abnormalities and significant DIC had an adverse effects on prognosis (P = 0.036 and P = 0.041, respectively), independent on other prognostic factors. These data indicate more aggressive biological nature of leukemic cells in patients with additional chromosome aberrations. Supplementary therapeutic strategies may be required for this subgroup of APL patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114710     DOI: 10.1007/BF02782196

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  Differentiation therapy of acute promyelocytic leukemia.

Authors:  Z Chen
Journal:  Chin Med J (Engl)       Date:  1996-03       Impact factor: 2.628

2.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

Authors:  S Castaigne; C Chomienne; M T Daniel; P Ballerini; R Berger; P Fenaux; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

3.  Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

Authors:  J L Slack; D C Arthur; D Lawrence; K Mrózek; R J Mayer; F R Davey; R Tantravahi; M J Pettenati; S Bigner; A J Carroll; K W Rao; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

4.  Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.

Authors:  L R Hiorns; G J Swansbury; J Mehta; T Min; M G Dainton; J Treleaven; R L Powles; D Catovsky
Journal:  Br J Haematol       Date:  1997-02       Impact factor: 6.998

5.  Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.

Authors:  R Berger; M Le Coniat; J Derré; D Vecchione; P Jonveaux
Journal:  Genes Chromosomes Cancer       Date:  1991-09       Impact factor: 5.006

Review 6.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.

Authors:  L Vahdat; P Maslak; W H Miller; A Eardley; G Heller; D A Scheinberg; R P Warrell
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

7.  Rapid method for obtaining high-quality chromosome banding in the study of hematopoietic neoplasia.

Authors:  A Novak; M Kruskic; M Ludoski; V Jurukovski
Journal:  Cancer Genet Cytogenet       Date:  1994-06

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

Authors:  P Fenaux; M C Le Deley; S Castaigne; E Archimbaud; C Chomienne; H Link; A Guerci; M Duarte; M T Daniel; D Bowen
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  10 in total

1.  Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).

Authors:  Peter H Wiernik; Zhuoxin Sun; Holly Gundacker; Gordon Dewald; Marilyn L Slovak; Elisabeth Paietta; Haesook T Kim; Frederick R Appelbaum; Peter A Cassileth; Martin S Tallman
Journal:  Med Oncol       Date:  2012-05-22       Impact factor: 3.064

2.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Authors:  S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

Review 3.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

4.  Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature.

Authors:  Burak Uz; Eylem Eliaçık; Ayse Işık; Salih Aksu; Yahya Büyükaşık; Ibrahim C Haznedaroğlu; Hakan Göker; Nilgün Sayınalp; Osman İ Ozcebe
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

Review 5.  A review of arsenic trioxide and acute promyelocytic leukemia.

Authors:  Kamran Alimoghaddam
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014-07-01

6.  PML is required for telomere stability in non-neoplastic human cells.

Authors:  M Marchesini; R Matocci; L Tasselli; V Cambiaghi; A Orleth; L Furia; C Marinelli; S Lombardi; G Sammarelli; F Aversa; S Minucci; M Faretta; P G Pelicci; F Grignani
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

7.  Trisomy 11 as an additional chromosome alteration in a child with acute promyelocytic leukemia with poor prognosis.

Authors:  Elenice Ferreira Bastos; Lidiane Alice Silva; Marcelo Coelho Ramos; Glicínia Pimenta; Paulo Ivo Cortez; Stella Beatriz Gonçalves de Lucena; Teresa de Souza Fernandez
Journal:  Case Rep Genet       Date:  2012-07-05

8.  Early mortality in acute promyelocytic leukemia: Potential predictors.

Authors:  Can Chen; Xilian Huang; Kaile Wang; Kuang Chen; Danquan Gao; Shenxian Qian
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

9.  Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Authors:  Lionel Adès; Pau Montesinos; Sabine Kayser; Ramy Rahmé; David Martínez-Cuadrón; Gabriel Ghiaur; Xavier Thomas; Marta Sobas; Agnes Guerci-Bresler; Ana Garrido; Arnaud Pigneux; Cristina Gil; Emmanuel Raffoux; Mar Tormo; Norbert Vey; Javier de la Serna; Olga Salamero; Eva Lengfelder; Mark J Levis; Pierre Fenaux; Miguel A Sanz; Uwe Platzbecker; Richard F Schlenk
Journal:  Leukemia       Date:  2020-02-19       Impact factor: 11.528

10.  Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Authors:  Sabine Kayser; Richard F Schlenk; Delphine Lebon; Martin Carre; Katharina S Götze; Friedrich Stölzel; Ana Berceanu; Kerstin Schäfer-Eckart; Pierre Peterlin; Yosr Hicheri; Ramy Rahme; Emmanuel Raffoux; Fatiha Chermat; Stefan W Krause; Walter E Aulitzky; Sophie Rigaudeau; Richard Noppeney; Celine Berthon; Martin Görner; Edgar Jost; Philippe Carassou; Ulrich Keller; Corentin Orvain; Thorsten Braun; Colombe Saillard; Ali Arar; Volker Kunzmann; Mathieu Wemeau; Maike De Wit; Dirk Niemann; Caroline Bonmati; Carsten Schwänen; Julie Abraham; Ahmad Aljijakli; Stephanie Haiat; Alwin Krämer; Albrecht Reichle; Martina Gnadler; Christophe Willekens; Karsten Spiekermann; Wolfgang Hiddemann; Carsten Müller-Tidow; Christian Thiede; Christoph Röllig; Hubert Serve; Martin Bornhäuser; Claudia D Baldus; Eva Lengfelder; Pierre Fenaux; Uwe Platzbecker; Lionel Adès
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.